AU2002314358A1 - Mycobacterial antigens expressed during latency - Google Patents

Mycobacterial antigens expressed during latency

Info

Publication number
AU2002314358A1
AU2002314358A1 AU2002314358A AU2002314358A AU2002314358A1 AU 2002314358 A1 AU2002314358 A1 AU 2002314358A1 AU 2002314358 A AU2002314358 A AU 2002314358A AU 2002314358 A AU2002314358 A AU 2002314358A AU 2002314358 A1 AU2002314358 A1 AU 2002314358A1
Authority
AU
Australia
Prior art keywords
expressed during
antigens expressed
mycobacterial antigens
during latency
latency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002314358A
Other versions
AU2002314358B2 (en
AU2002314358C1 (en
Inventor
Tobias Hampshire
Brian William James
Philip Marsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Health
Original Assignee
The Secretary Of State For Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB0116385A priority Critical patent/GB0116385D0/en
Priority to GB0116385.6 priority
Priority to GB0123993.8 priority
Priority to GB0123993A priority patent/GB0123993D0/en
Application filed by The Secretary Of State For Health filed Critical The Secretary Of State For Health
Priority claimed from AU2002314358A external-priority patent/AU2002314358C1/en
Priority to AU2002314358A priority patent/AU2002314358C1/en
Priority to PCT/GB2002/003052 priority patent/WO2003004520A2/en
Publication of AU2002314358A1 publication Critical patent/AU2002314358A1/en
Assigned to HEALTH PROTECTION AGENCY reassignment HEALTH PROTECTION AGENCY Amend patent request/document other than specification (104) Assignors: HEALTH PROTECTION AGENCY
Publication of AU2002314358B2 publication Critical patent/AU2002314358B2/en
Application granted granted Critical
Publication of AU2002314358C1 publication Critical patent/AU2002314358C1/en
Assigned to THE SECRETARY OF STATE FOR HEALTH reassignment THE SECRETARY OF STATE FOR HEALTH Request for Assignment Assignors: HEALTH PROTECTION AGENCY
Application status is Ceased legal-status Critical
Anticipated expiration legal-status Critical

Links

AU2002314358A 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency Ceased AU2002314358C1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB0116385A GB0116385D0 (en) 2001-07-04 2001-07-04 Mycobacterial antigens expressed during latency
GB0116385.6 2001-07-04
GB0123993.8 2001-10-05
GB0123993A GB0123993D0 (en) 2001-10-05 2001-10-05 Mycobacterial antigens expressed during latency
AU2002314358A AU2002314358C1 (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency
PCT/GB2002/003052 WO2003004520A2 (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002314358A AU2002314358C1 (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency
AU2008243118A AU2008243118A1 (en) 2001-07-04 2008-11-05 Mycobacterial antigens expressed during latency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008243118A Division AU2008243118A1 (en) 2001-07-04 2008-11-05 Mycobacterial antigens expressed during latency

Publications (3)

Publication Number Publication Date
AU2002314358A1 true AU2002314358A1 (en) 2003-05-22
AU2002314358B2 AU2002314358B2 (en) 2008-08-14
AU2002314358C1 AU2002314358C1 (en) 2009-03-26

Family

ID=26246282

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002314358A Ceased AU2002314358C1 (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency
AU2008243118A Abandoned AU2008243118A1 (en) 2001-07-04 2008-11-05 Mycobacterial antigens expressed during latency

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008243118A Abandoned AU2008243118A1 (en) 2001-07-04 2008-11-05 Mycobacterial antigens expressed during latency

Country Status (6)

Country Link
US (3) US7393540B2 (en)
EP (2) EP1404706A2 (en)
JP (1) JP2005508613A (en)
AU (2) AU2002314358C1 (en)
CA (1) CA2453173C (en)
WO (1) WO2003004520A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806093D0 (en) * 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
EP1401867A2 (en) 2001-06-22 2004-03-31 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
CA2453173C (en) 2001-07-04 2013-12-10 Health Protection Agency Mycobacterial antigens expressed during latency
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
AU2003242504A1 (en) * 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2004067718A2 (en) * 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
ES2231037B1 (en) 2003-10-31 2005-12-16 Archivel Technologies, Sl Useful immunotherapic agent for the combined treatment of tuberculosis in association with other pharmacos.
EP1868640A1 (en) * 2005-03-31 2007-12-26 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
EP1904848A2 (en) * 2005-04-29 2008-04-02 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
KR101188045B1 (en) * 2005-06-23 2012-10-05 스태튼스 세룸 인스티튜트 Tuberculosis vaccines comprising antigens expressed during the latent infection phase
AT530569T (en) 2005-07-01 2011-11-15 Forsyth Dental In Ry For Children Fa Assays for the detection of tuberculosis antigenes, and vaccines
AT466876T (en) * 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogenic constructs
US7601357B2 (en) * 2005-12-07 2009-10-13 University Of Central Florida Research Foundation, Inc. Targeting of long chain triacylglycerol hydrolase gene for tuberculosis treatment
US20070231816A1 (en) * 2005-12-09 2007-10-04 Baylor Research Institute Module-Level Analysis of Peripheral Blood Leukocyte Transcriptional Profiles
JP2009528545A (en) * 2006-03-02 2009-08-06 ザ ユーエービー リサーチ ファウンデーション Mycobacterium disease detection, treatment, and drug development
ES2307402B1 (en) 2006-10-30 2009-09-30 Archivel Farma, S.L. Profilactic vaccine against tuberculosis.
EA201170088A1 (en) * 2008-06-25 2011-10-31 Бейлор Рисёч Инститьют Transcription signature of blood infection mycobacterium tuberculosis
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2335177B1 (en) 2008-09-19 2011-02-28 Archivel Farma, S.L. Proper immunotherapeutic agent for the primary profilaxis of tuberculosis.
WO2011063283A2 (en) 2009-11-20 2011-05-26 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
US20110129817A1 (en) * 2009-11-30 2011-06-02 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
ITRM20100411A1 (en) * 2010-07-23 2012-01-24 Massimo Amicosante Use of amino acid sequences from Mycobacterium tuberculosis or their corresponding nucleic acids for the detection and prevention of tuberculosis infection on diagnostic kit and vaccine.
WO2012093137A1 (en) 2011-01-04 2012-07-12 Archivel Farma, Sl Liposome formulation suitable for treating or preventing tuberculosis
EP2471511A1 (en) 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
US20140363465A1 (en) * 2011-04-04 2014-12-11 Beth Israel Deaconess Medical Center, Inc. Mycobacterial vaccine vectors and methods of using the same
US10017550B2 (en) * 2011-08-30 2018-07-10 The Uab Research Foundation Mycobacterium tuberculosis porins and toxins and related methods
US20140004151A1 (en) * 2011-09-30 2014-01-02 La Jolla Institute For Allergy And Immunology Antigens and Epitopes Derived From Mycobacterium Tuberculosis
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
US10197560B2 (en) 2013-06-27 2019-02-05 The Brigham And Women's Hospital, Inc. Methods and systems for determining M. tuberculosis infection
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
GB201400819D0 (en) * 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
CN107110862A (en) * 2014-08-15 2017-08-29 牛津免疫科技有限公司 Mycobacterium tuberculosis protein

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
DE4221858A1 (en) 1992-07-03 1994-01-05 Becker Carl Chemie Gmbh Adducts of 0,0-dialkyl dithiophosphoric acids to unsaturated compounds, processes for their preparation and their use as lubricant additives
US6583266B1 (en) 1993-08-19 2003-06-24 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics
US5783386A (en) 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
US5876931A (en) 1994-12-09 1999-03-02 Rpms Technology Limited Identification of genes
US6572865B1 (en) 1995-06-15 2003-06-03 University Of Victoria Innovation And Development Corporation Mycobacterium tuberculosis DNA sequences encoding immunostimulatory peptides and methods for using same
CZ126699A3 (en) 1996-10-11 1999-09-15 Corixa Corporation Polypeptide containing antigenic part of soluble antigen m. tuberculosis or variant of said antigen, dna molecule encoding such polypeptide, expression vector, host cell, diagnostic methods of m. tuberculosis infection and diagnostic kits
US5998194A (en) 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
CA2197524A1 (en) 1996-02-22 1997-08-22 Bradley Stuart Dehoff Polyketide synthase genes
CA2249208A1 (en) 1996-03-27 1997-10-02 The Johns-Hopkins University Stationary phase, stress response sigma factor from mycobacterium tuberculosis, and regulation thereof
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
GB9711389D0 (en) 1997-06-04 1997-07-30 Univ Wales The Bacterial pheromones and uses therefor
US6436409B1 (en) 1997-07-16 2002-08-20 Institut Pasteur Polynucleotide functionally coding for the LHP protein from Mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
AU9200398A (en) 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in granulocytic cells
GB9723630D0 (en) 1997-11-07 1998-01-07 Stanford Rook Ltd M.vaccae preparation and its use
US6183957B1 (en) * 1998-04-16 2001-02-06 Institut Pasteur Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria
EP1075485A4 (en) 1998-05-05 2004-12-15 Gene Logic Inc A process to study changes in gene expression in t lymphocytes
US6892139B2 (en) 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
GB9904773D0 (en) 1999-03-02 1999-04-28 Microbiological Res Authority Culture of mycobacteria
US6573361B1 (en) 1999-12-06 2003-06-03 Monsanto Technology Llc Antifungal proteins and methods for their use
US6613553B1 (en) * 2000-02-04 2003-09-02 St. Jude Children's Research Hospital Enoyl reductases and methods of use thereof
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
EP1401867A2 (en) 2001-06-22 2004-03-31 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
CA2453173C (en) 2001-07-04 2013-12-10 Health Protection Agency Mycobacterial antigens expressed during latency
GB0125535D0 (en) 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency

Similar Documents

Publication Publication Date Title
AU2002309706A1 (en) Novel meningitis conjugate vaccine
AU2002339705A1 (en) Optical device
AU2002251205A1 (en) Multi-modal interface
AU2002359414A1 (en) Interposer
AU2002316685A1 (en) Arm stockinettes
AU2002360685A1 (en) Late-pcr
AU2002254570A1 (en) Epitope sequences
AU2002351574A1 (en) Improved self-chekout apparatus
AU2002360508A1 (en) Substituted hydroxyethylamines
AU2002310044A1 (en) Headwall
AU2002310642A1 (en) Loudspeaker
AU2002325199A1 (en) Beta-amyloid-analogue-T-cell epitop vaccine
AU2002352394A1 (en) Focussed antibody technology
AU2002226567A1 (en) Expander device
AU2002353213A1 (en) Optical device
AU2003241104A1 (en) Glucan-based vaccines
AU2002363250A1 (en) Pyrazole-amides and-sulfonamides
AU2002337489A1 (en) Inexsufflator
AU2002244337A1 (en) Vaccines
AU2002367146A1 (en) Storage device
AU2002359163A1 (en) New use
AU2002364081A1 (en) Image-rendering device
AU2002253291A1 (en) Application synchronisation
AU2002339487A1 (en) Microscope
EP1263222A3 (en) Projector device